This study evaluated the efficacy and safety of adding Actos (pioglitazone) to metformin treatment in women with polycystic ovary syndrome (PCOS) who did not respond optimally to metformin alone. The study found that in women whose PCOS symptoms were not improved by metformin, the addition of Actos led to reductions in insulin levels, insulin resistance, and androgen levels, as well as improved menstrual regularity, without any safety issues.